Reservoir-based drug delivery systems utilizing microtechnology

Advanced Drug Delivery Reviews

Volumn 64, Issue 14, 2012, Pages 1590-1602

  Stevenson, Cynthia L ^a   Santini, John T ^a   Langer, Robert ^b  

^a On Demand Therapeutics Inc   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Controlled release; Implant; MEMS; Microneedle; Micropump; Ocular; On demand; Pulsatile

Indexed keywords

CONTROLLED RELEASE; MICRO PUMP; MICRONEEDLES; OCULAR; ON DEMAND; PULSATILE;

IMPLANTS (SURGICAL); MEMS; PATIENT TREATMENT;

DRUG DELIVERY;

BEVACIZUMAB; CARMUSTINE; DOCETAXEL; EXENDIN 4; FLUOCINOLONE ACETONIDE; GANCICLOVIR; HISTRELIN; INFLUENZA VACCINE; INSULIN; LEUPRORELIN; LOCAL ANESTHETIC AGENT; NANOCHANNEL; NANOCOATING; PACLITAXEL; PILOCARPINE; PIMECROLIMUS; RAPAMYCIN; RECOMBINANT PARATHYROID HORMONE; SUFENTANIL; SULFORHODAMINE B;

ANALYTICAL PARAMETERS; CYTOMEGALOVIRUS RETINITIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HUMAN; IMPLANT; MICROTECHNOLOGY; NEEDLE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RESERVOIR; REVIEW; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EQUIPMENT DESIGN; HUMANS; MICROTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 84868204663     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.02.005     Document Type: Review

References (103)

1. Mandal D.C., Mandal M. Current status and future prospects of new drug delivery system. Pharma Times Apr. 2010, 42.
2. Kaparissides C., Alexandridou S., Kotti K., Chaididou S. Advanced Drug Delivery Systems: New Developments, New Technologies October 2006, AzoM.com Pvt.L Ltd.
3. Langer R., Peppas N.A. Advances in biomaterials, drug delivery and bionanotechnology. AICHE J. 2003, 49:2990-3006.
4. Hilt J.Z., Peppas N.A. Microfabricated drug delivery devices. Int. J. Pharm. 2005, 306:15-23.
5. Verma R.K., Garg S. Drug delivery technologies and future directions. Pharm. Technol. 2001, 25:1-14.
6. Rosen H., Abribat T. The rise and rise of drug delivery. Nat. Rev. Drug Discov. 2005, 4:381-385.
7. Thomson Physicians' Desk Reference 2009, Thomson Publishing, Montvale, N.J. 63th Edition.
8. Ahmed A., Bonner C., Desai T. Bioadhesive microdevices with multiple reservoirs: a new platform for oral drug delivery. J. Control. Release 2002, 81:291-306.
9. Tao S.L., Desai T.A. Micromachined devices: the impact of controlled geometry for cell-targeting to bioavailability. J Control. Release 2005, 109:127-138.
10. Ainslie K.M., Desai T.A. Microfabricated implant for applications in therapeutic delivery, tissue engineering and biosensing. Lab Chip 2008, 8:1864-1878.
11. Ainslie K.M., Lowe R.D., Beaudette T.T., Petty L., Bachelder E.M., Desai T.A. Microfabricated devices for enhanced bioadhesive drug delivery: attachment to and small-molecule release through a cell monolayer under flow. Small 2009, 5:2857-2863.
12. Tao S.L., Desai T.A. Microfabrication of multilayer, asymetric, polymeric devices for drug delivery. Adv. Mater. 2005, 17:1625-1630.
13. Tao S.L., Desai T.A. Gastrointestinal patch systems for oral drug delivery. Drug Discov. Today. 2005, 10:909-915.
14. Nuxoll E.E., Siegel R.A. BioMEMS devices for drug delivery. IEEE Eng. Med. Biol. Jan/Feb 2009, 31-39.
15. Aroro A., Prausnitz M., Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 2008, 8:227-236.
16. Staples M., Daniel K., Cima M.J., Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm. Res. 2006, 23:847-863.
17. Matriano J., Cormier M., Johnson J., Young W., Buttery M., Nyam K., Daddona P. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 2002, 19:1653-1664.
18. Chandrasekara S., Brazzle J., Frazier A. Surface machined metallic microneedles. J. Microelectromech. Syst. 2003, 12:281-288.
19. Zahn J., Talbot N., Liepmann D., Pisano A. Microfabricated polysilicon microneedles for minimally invasive biomedical devices. Biomed. Microdevices 2000, 2:295-303.
20. Zahn J., Deshmekh A., Pisano A., Liepmann D. Continuous on-chip micropumping from microneedled enhance drug delivery. Biomed. Microdevices 2004, 6:183-190.
21. Teo M.A.L., Shearwood C., Ng K.C., Lu J., Moochhala S. In vitro and in vivo characterization of MEMS microneedles. Biomed. Microdevices 2005, 7:47-52.
22. McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., Prausnitz M.R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13755-13760.
23. Stoeber B., Liepmann D. Arrays of hollow out-of-plane microneedles for drug delivery. J. Microelectromech. Syst. 2005, 14:472-479.
24. Sivamani R., Stoeber B., Wu G., Zhai H., Liepmann D., Maibach H. Clinical microneedle injection of methyl nicotinate: stratum corneum penetration. Skin Res. Technol. 2005, 11:152-156.
25. Griss P., Stemme G. Side-opened out-of-plane microneedles for microfluidic transdermal liquid transfers. J. Microelectromech. Syst. 2003, 12:296-301.
26. Roxhed N., Gasser C., Griss P., Holzapfel G., Stemme G. Penetration enhanced ultrashorp microneedles and prediction in skin interaction for efficient transdermal drug delivery. J. Microelectromech. Syst. 2007, 16:1429-1440.
27. Gardeniers H., Luttge R., Bereschot E., de Boer M., Yeshurun S., Hefetz M., van't Oever R., van den Berg A. Silicon micromachines hollow microneedles for transdermal liquid transport. J. Microelectromech. Syst. 2003, 12:855-862.
28. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
29. http://www.debiotech.com/.
30. Roxhed N., Griss P., Stemme G. Membrane-sealed hollow microneedles and related administration schemes for transdermal drug delivery. Biomed. Microdevices 2008, 10:271-279.
31. Nordquist L., Roxhed N., Griss P., Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm. Res. 2007, 24:1381-1387.
32. Hafeli U.O., Mikhtari A., Liepmann D. In vivo evaluation of a microneedle-based miniature syringe for intradermal drug delivery. Biomed. Microdevices 2009, 11:943-950.
33. Davis S.P., Martanto W., Allen M.G., Prausnitz M.R. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE T. Bio-Med. Eng. 2005, 52:909-915.
34. Patel S.R., Lin A.S.P., Edelhauser H.F., Prausnitz M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 2010, 28:166-176.
35. http://www.valeritas.com/.
36. Sullivan S.P., Koutsonanos D.G., Martin M.D.P., Lee J.W., Zarnitsyn V., Choi S.O., Murthy N., Compans R.W., Skountzou I., Prausnitz M.R. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 2010, 16:915-920.
37. Kommareddy S., Boudner B.C., Oh S., Kwon S.Y., Singh M., O'Hagan D.T. Dissolvable microneedle patches for the delivery of cell culture derived influenza vaccine antigens. J. Pharm. Sci. 2012, 101:1021-1027.
38. Grayson A.C.R., Shawgo R.S., Johnson A.M., Flynn N.T., Li Y., Cima M.J., Langer R. A BioMEMS review: MEMS technology for physiologically integrated devices. Proc. IEEE 2009, 92:6-21.
39. Sakamoto J.H., van de Ven A.L., Godin B., Blanco E., Serda R.E., Grattoni A., Ziemys A., Bouramrani A., Hu T., Ranganathan S.I., De Rosa E., Martinez J.O., Smid C.A., Chchana R.M., Lee S.Y., Srinavasan S., Landry M., Meyn A., Tasciotti E., Liu X., Decuzzi P., Ferrari M. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 2010, 62:57-89.
40. Nisar A., Afzulpurkar N., Mahaisavariya B., Tuantranont A. MEMS-based micropumps in drug delivery and biomedical applications. Sensor. Actuat. B-Chem. 2008, 130:917-942.
41. Receveur R.A.M., Linemans F.W., de Rooij N.F. Microsystem technologies for implantable applications. J. Micromech. Microeng. 2007, 17:R50-R80.
42. Choonara Y.E., Pillay V., Danckwerts M.P., Carmichael T.R., Du Toit L.C. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J. Pharm. Sci. 2010, 99:2219-2239.
43. Eljarrat-Binstock E., Pe'er J., Domb A.J. New techniques for drug delivery to the posterior eye segment. Pharm. Res. 2010, 27:530-543.
44. Mansoor S., Kuppermann B.D., Kenney M.C. Intraocular sustained release delivery systems for triamcinolone acetonide. Pharm. Res. 2009, 26:770-784.
45. http://www.psivida.com/products.html.
46. Sanborn G.E., Anand R., Torti R.E., Nightingale S.D., Cal S.X., Yates B., Aston P., Smith T.J. Sustained release ganciclovir therapy for treatment of cytomegalovirus retinitis; uses of an intravitreal device. Arch. Ophthalmol. 1992, 110:188-195.
47. Smith T.J., Pearson P.A., Blandford D.L., Brown J.D., Goins K.A., Hollins J.L., Schmiesser E.T., Glavinos P., Baldwin L.B., Ashton P. Intravitreal sustained release ganciclovir. Arch. Ophthalmol. 1992, 110:255-258.
48. Mruthyunjaya P., Khalatbari D., Yang P., Stinnett S., Tano R., Ashton P., Guo H., Nazzar M., Jaffe G.J. Efficacy of low release rate fluocinolone acetonide intravitreal implants to treat experiments uveitis. Arch. Ophthalmol. 2006, 124:1012-1018.
49. Callanan D.G., Jaffe G.J., Martin D.F., Pearson P.A., Comstock T.L. Treatment of posterior uveitis with a flucinolone acetonide implant. Arch. Ophthalmol. 2008, 126:1191-1201.
50. http://www.alimerasciences.com/Products/iluvien.aspx.
51. Kane F.E., Burdan J., Cutino A., Green K.E. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin. Drug Del. 2008, 5:1039-1046.
52. Campochiaro P.A., Brown D.M., Pearson A., Ciulla T., Boyer D., Holz F.G., Tolentino M., Gupta A., Duarte L., Madreperla S., Gonder J., Kapik B., Billman K., Kane F. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011, 118:626-635.
53. http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID=574002.
54. Molokhia S.A., Sant H., Simonis J., Bishop C.J., Burr R.M., Gale B.K., Ambati B.K. The capsule drug device: novel approach for drug delivery to the eye. Vision Res. 2010, 50:680-685.
55. Grayson A.C.R., Choi I.S., Tyler B.M., Wang P.P., Brem H., Cima M.J., Langer R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2003, 2:767-772.
56. Kim G.Y., Tyler B.M., Tupper M.M., Karp J.M., Langer R.S., Brem H., Cima M.J. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J. Control. Release 2007, 123:172-178.
57. Grayson A.C.R., Cima M.J., Langer R. Molecular release from a polymeric microreservoir device: influence of chemistry, polymer swelling and loading on device performance. J. Biomed. Mater. Res. A 2004, 69A:502-512.
58. Kuppermann B.D. Implant delivery of corticosteroids and other pharmacologic agents. Retina 2006: Emerging New Concepts. American Academy of Ophthalmology Annual Meeting, Las Vegas, NV Nov 10-11 2006.
59. 59.L.D. Piveteau, H. Hofmann, F. Neftel, Anisotropic nanoporous coatings for medical implants. EP Patent 1,891,988 (2008).
60. Verhey S., Adostoni P., Dawkins K.D., Dens J., Rutsch W., Carrie D., Schofer J., Lotan C., Dubois C.L., Cohen S.A., Fitzgerald P.J., Lansky A.J. The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arties) Trial. J. Am. Coll. Cardiol. Intv. 2009, 2:205-214.
61. Capodanno D., Dipasqua F., Tamburino C. Novel drug-eluting stents in the treatment of de novo coronary lesions. Vasc. Health Risk Manag. 2011, 7:103-118.
62. Grube E., Schofer J., Hauptmann K.E., Nickenig G., Curzen N., Allocco D.J., Dawkins K.D. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer. J. Am. Coll. Cardiol. Intv. 2010, 3:431-438.
63. Garg S., Serruys P.W. Coronary stents: looking forward. J. Am. Coll. Cardiol. 2010, 56:S43-S78.
64. Martin F., Walczak R., Boiarski A., Cohen M., West T., Casentino C., Ferrari M. Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J. Control. Release 2005, 102:123-133.
65. Lesinski G., Sharma S., Varker K., Sinha P., Ferrari M., Carson W. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed. Microdevices 2005, 7:71-79.
66. Pricl S., Ferrone M., Fermeglia M., Amato F., Cosentino C., Cheng M.M., Walczak R., Ferrari M. Multiscale modeling of protein transport in silicon membrane nanochannels. Part 1. Derivation of molecular parameters from computer simulations. Biomed. Microdevices 2006, 8:277-290.
67. Eijkel J.C.T., van den Berg A. Nanofluidics: what is it and what can we expect from it?. Microfluid. Nanofluid. 2005, 5:249-267.
68. Sinha P.M., Valco G., Sharma S., Liu X., Ferarri M. Nanoengineered device for drug delivery application. Nanotechnology 2004, 15:S585-S589.
69. Paisley A.N., Trainer P.J. Recent advances in the treatment of acromegaly. Recent Adv. Investig. Drugs 2006, 15:251-256.
70. Gardner P. Use of a nanopore membrane in novel a drug delivery device. Future Drug Delivery June 2006, 59-60.
71. Stevenson C.L., Theeuwes F., Wright J.C. Osmotic implantable delivery systems. Handbook of Pharmaceutical Controlled Release Technology 2000, 225-253. Marcel Dekker, Inc., New York. D. Wise (Ed.).
72. Wright J.C., Leonard S.T., Stevenson C.L., Beck J.C., Chen G., Jao R.M., Johnson P.A., Leonard J., Skowronski R.J. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release 2001, 75:1-10.
73. Stevenson C.L. Formulation of leuprolide at high concentration for delivery from a one year implant. Protein Formulation and Delivery 2007, 153-175. Marcel Dekker, Inc., NY. 2nd Edition. E.J. McNally, J.E. Hastedt (Eds.).
74. Cukierski M.J., Johnson P.A., Beck J.C. Chronic (60 week) toxicity study of DUROS leuprolide implants in dogs. Int. J. Toxicol. 2001, 20:369-381.
75. Fisher D.M., Kellett N., Lenhardt R. Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. Anesthesiology 2003, 99:929-937.
76. Corp D. Press Release from. http://phx.corporate-ir.net/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=459693&highlight.
77. http://www.intarcia.com.
78. Yang B., Negulescu C., D'vas R., Eftimie C., Carr J., Lautenbach S., Horwege K., Mercer C., Ford D., Alessi T. Stability of ICTA 560 for continuous subcutaneous delivery of Exenatide at body temperature for 12months. 2009 Diabetes Technology Meeting, Long Beach, CA April 3, 2009.
79. Henry R.R., Cuddig R., Rosenstock J., Alessi T., Luskey K. Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes. European Association for the Study of Diabetes (EASD) 46th Annual Meeting: Abstract 78 September 22, 2010.
80. Yang B., Alessi T., Rohloff C., Mercer R., Negulescu C., Lautenbach S., Gumucio J., Guo M., Weeks E., Carr J., Ford D. Continuous delivery of proteins and peptides at consistent rates for at least 3months form the DUROS® device. AAPS 2008 Meeting, Atlanta Georgia Nov 18, 2008, Poster T3150.
81. Rohloff C.M., Alessi T.R., Yang B., Dahms J., Carr J.P., Lautenbach S.D. DUROS® technology delivers peptides and proteins at consistent rate continuously for 3 to 12months. J. Diabetes Sci. Technol. 2008, 2:461-467.
82. Ryu W.H., Huang Z., Prinz F.B., Goodman S.B., Fasching R. Biodegradable microosmotic pump for long-term and controller lease of basic fibroblast growth factor. J. Control. Release 2007, 124:98-105.
83. Lo R., Kuwahar K., Li P.Y., Saati S., Agrawal R.N., Humayun M.S., Meng E. A passive MEMS drug delivery pump for treatment of ocular diseases. Biomed. Microdevices 2009, 11:959-970.
84. Li P.Y., Shih J., Lo R., Saati S., Agrawal R., Humayun M.S., Tai Y.C., Meng E. An electrochemical intraocular drug delivery device. Sensor. Actuat. A-Phys. 2008, 143:41-48.
85. Pirmoradi F.N., Jackson J.K., Burt H.M., Chaio M. On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device. Lab Chip 2011, 11:2744-2752.
86. Elman N.M., Ho Duc H.L., Cima M.J. An implantable MEMS drug delivery device for rapid delivery in ambulatory emergency care. Biomed. Microdevices 2009, 11:625-631.
87. Chung A.J., Huh Y.S., Erickson D. A robust, electrochemically driven microwell drug delivery system for controlled vasopressin release. Biomed. Microdevices 2009, 11:861-867.
88. Low L.M., Seetharaman S., He K.Q., Madou M.J. Microactuators toward microvalves for responsive controlled drug delivery. Sensor. Actuat. B-Chem. 2000, 1:149-160.
89. Santini J.T., Cima M.J., Langer R. A controlled-release microchip. Nature 1999, 397:335-338.
90. Santini J.T., Richards A.C., Scheidt R.A., Cima M.J., Langer R. Microchips as implantable drug delivery devices. Agnew. Chem. Int. Edit. 2000, 39:2396-2407.
91. Shawgo R., Grayson A.C.R., Li Y., Cima M.J. BioMEMS for drug delivery. Curr. Opin. Solid State Mater. Sci. 2002, 6:329-334.
92. Li Y., Ho Duc H.L., Tyler B., Williams T., Tupper M., Langer R., Brem H., Cima M.J. In vivo delivery of BCNU from a MEMS device to a tumor model. J. Control. Release 2005, 106:138-145.
93. Li Y., Shawgo R., Tyler B., Henderson P., Gobel J., Rosenberg A., Storm P.B., Langer R., Brem H., Cima M.J. In vivo release from a drug delivery MEMS device. J. Control. Release 2004, 100:211-291.
94. http://www.ondemandtx.com.
95. Grayson A.C.R., Shawgo R.S., Li Y., Cima M.J. Electronic MEMS for triggered delivery. Adv. Drug Delivery Rev. 2004, 56:173-184.
96. Prescott J.H., Lipka S., Baldwin S., Sheppard N.F., Maloney J.M., Coppeta J., Yomtov B., Stables M.A., Santini J.T. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat. Biotechnol. 2006, 24:437-438.
97. Maloney J.M., Uhland S.A., Polito B.F., Sheppard N.F., Pelta C.M., Santini J.T. Electrothermally activated microchips for implantable drug delivery and biosensing. J. Control. Release 2005, 109:244-255.
98. Prescott J.H., Krieger T.J., Lipka S., Staples M.A. Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm. Res. 2007, 24:1252-1261.
99. Proos E.R., Prescott J.H., Staples M.A. Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array. Pharm. Res. 2008, 25:1387-1395.
100. Ainslie K.M., Thakar R.G., Bernards D.A., Desai T.A. Inflammatory response to implanted nanostructured materials. Biological Interactions on Material Surfaces 2009, 355-371. Springer, New York. D.A. Puleo, R. Bizios (Eds.).
101. Ainslie K.M., Tao S.L., Popat K.C., Desai T.A. In vitro immunogenicity of silicon based micro and nanostructured surfaces. ACS Nano 2008, 2:1076-1084.
102. Muthusubramaniam L., Lowe R., Fissell W.H., Li L., Marchant R.E., Desai T.A., Roy S. Hemocompatibility of silicon based substrates for biomedical implant applications. Ann. Biomed. Eng. 2011, 39:1296-1305.
103. Voskerician G., Shive M.S., Shawgo R.S., von Recum H., Anderson J.M., Cima M.J., Langer R. Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials 2003, 24:1959-1967.